Mai Capital Management Avadel Pharmaceuticals PLC Transaction History

Mai Capital Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$12.55 - $17.22 $56,788 - $77,920	4,525 Added 4.23%	111,605 $1.89 Million
Q4 2023 Feb 09, 2024	BUY	$9.64 - $14.59 $596,301 - $902,493	61,857 Added 136.78%	107,080 $1.51 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $62,284 - $96,691	-6,047 Reduced 11.79%	45,223 $465,000
Q2 2023 Aug 02, 2023	BUY	$8.48 - $16.48 $434,769 - $844,929	51,270 New	51,270 $844,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.